(Q35552617)

8 August 2017

1 reference

title

Pros and cons of adjuvant interferon in the treatment of melanoma (English)

1 reference

8 August 2017

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma (English)

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

18 March 2024

2

Vernon K Sondak

1 reference

8 August 2017

Michael S. Sabel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530498

18 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14530498

18 March 2024

publication date

1 January 2003

1 reference

full work available at URL

8 August 2017

https://academic.oup.com/oncolo/article-pdf/8/5/451/41840229/oncolo_8_5_451.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14530498

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.8-5-451

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.8-5-451

18 March 2024

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

https://academic.oup.com/oncolo/article-pdf/8/5/451/41840229/oncolo_8_5_451.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

18 March 2024

1 reference

8 August 2017

volume

8

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

451-458

1 reference

8 August 2017

cites work

Cancer statistics, 2001

1

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

18 March 2024

2

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma

18 March 2024

5

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Long-term adjuvant therapy of high-risk malignant melanoma with interferon alpha 2b

18 March 2024

7

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Results of adjuvant interferon study in WHO melanoma programme

18 March 2024

8

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

18 March 2024

10

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

18 March 2024

11

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

18 March 2024

12

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

18 March 2024

13

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

18 March 2024

14

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

18 March 2024

15

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

18 March 2024

16

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

18 March 2024

17

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

18 March 2024

18

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Adjuvant therapy of malignant melanoma

18 March 2024

20

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

18 March 2024

21

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

The unfulfilled promise of melanoma vaccines

18 March 2024

22

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Impact of clinical trials on the treatment of melanoma

18 March 2024

23

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Vaccine therapy for patients with melanoma

18 March 2024

24

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

18 March 2024

26

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

18 March 2024

27

1 reference

https://api.crossref.org/works/10.1634/THEONCOLOGIST.8-5-451

18 March 2024

Identifiers

1 reference

8 August 2017

1 reference